The Alzheimer’s Therapeutics Market was valued at $3.78 billion in 2023 and is projected to reach $13.42 billion by 2032, with a CAGR of 15.14% during 2024-2032. The rising prevalence of Alzheimer’s disease, with an estimated 55 million people globally affected in 2023, is driving market growth. In the US, 6.68 million people have Alzheimer’s disease.

Key companies in the Alzheimer’s Therapeutics Market include Eisai Co. Ltd, Biogen Inc, F. Hoffmann La Roche Ltd, Eli Lilly and Company, Novartis AG, and more. The market is segmented by product, with cholinesterase inhibitors leading the way, and by end-user, with hospital pharmacies dominating in 2023.

North America led the Alzheimer’s therapeutics market in 2023, with over 38% revenue share, while Asia Pacific is expected to grow the fastest during the forecast period. Recent developments include FDA approval of Eisai Co., Ltd.’s Leqembi for Alzheimer’s treatment and collaborations for new therapeutic avenues.

SNS Insider offers in-depth reports on various markets, including Alzheimer’s Therapeutics, Parkinson’s Disease Treatment, Digital Neuro Biomarkers, Neuroscience, and Neurocognitive Assessment and Rehabilitation. Their aim is to provide clients with accurate market data and insights to make informed decisions in a changing environment.

Read more at GlobeNewswire: Alzheimer’s Therapeutics Market Size Projected to Reach